The largest database of trusted experimental protocols

25 protocols using recombinant human trail

1

Matrigel and Growth Factor Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Matrigel (Matrigel® matrix basement membrane growth factor reduced) was sourced from Corning (New York City, NY, USA). Human recombinant TRAIL was purchased from R&D Systems (Minneapolis, MN, USA). Human recombinant VEGF-A and FGF-2 were purchased from Sigma-Aldrich (St. Louis, MO, USA).
+ Open protocol
+ Expand
2

Investigating Cancer Cell Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human renal carcinoma (Caki-1 and A498), human lung cancer (A549), and human breast cancer (MDA-MB361) were procured from American Type Culture Collection (Manassas, VA, USA). Human recombinant TRAIL, zVAD-fmk, and anti-survivin were provided by the R&D system (Minneapolis, MN, USA). MG132, PD98059, AG-490, compound C, and NVP-BEZ235 were supplied from Calbiochem (San Diego, CA, USA). Dexamethasone, cycloheximide, AR-A014418, PP242, BAY11-7082, rapamycin, and anti-actin were provided from Sigma Chemical Co. (St. Louis, MO, USA). Anti-PARP, anti-Bcl-xL, anti-DR5, anti-cIAP1, anti-caspase-8, anti-phospho-GSK3β, and anti-GSK3β were provided by Cell Signaling Technology (Beverly, MA, USA). Anti-Bim, anti-Bax, and anti-XIAP were obtained from BD Biosciences (San Jose, CA, USA). Anti-Mcl-1, anti-Bcl-2, anti-cIAP2, and anti-Cbl were purchased from Santa Cruz Biotechnology (St. Louis, MO, USA). SB203580, SP600125, and anti-c-FLIP(L) were obtained from Enzo Life Sciences (San Diego, CA, USA). Anti-DR4 were obtained from Abcam (Cambridge, MA, USA). pCMV-Myc-Cbl plasmid was a gift from Dr. S. J. Kim (CHA University, Korea). GSK3betaS9A (1016) was a gift from Scott Friedman (Addgene plasmid # 49492; http://n2t.net/addgene:49492; RRID: Addgene_49492) [36 (link)].
+ Open protocol
+ Expand
3

Sensitizing Cells to TRAIL-Induced Death

Check if the same lab product or an alternative is used in the 5 most similar protocols
The sensitizing effect was achieved with pre-treatment for 24 h with the bivalent Smac mimetic BV6 (kindly provided by Genentech). Cell death was induced with treatment with human recombinant TRAIL (R&D Systems, Wiesbaden, Germany). Cell death was inhibited with zVAD.fmk (Bachem, Heidelberg, Germany), anti-TRAIL antibody (No. 2E5; Enzo Life Sciences, Lörrach, Germany), zAAD-CMK (Calbiochem Merck, Darmstadt, Germany) and Etanercept (Enbrel, Merck, Darmstadt, Germany).
+ Open protocol
+ Expand
4

TRAIL-Induced Cell Viability Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
The LoVo cells were seeded at a density of 1 × 104 cells/cm2 in 96-well plates and cultured for 24 h. The cells were treated with human recombinant TRAIL (R&D systems), incubated for 24 h, treated with 10 μL of water soluble tetrazolium salt (WST)-1 reagent (Roche, Indianapolis, IN, USA), and incubated for 1 h at standard culture conditions. Then, the absorbance was measured using a microplate reader (Molecular Devices, San Jose CA, USA) at 450 nm.
+ Open protocol
+ Expand
5

Establishment of TRAIL-Resistant Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
In order to secure stable TRAIL-resistant cells, parental LS-LiM6 or DLD1 cells were treated with 100 ng/ml human recombinant TRAIL (R&D Systems, Danvers, MA, #375-TEC) for 24 h. The apoptotic cells were then removed and the surviving cells were propagated in the presence of 10 ng/ml TRAIL for a total of five cycles resulting in stable TRAIL-resistant cell lines LiM6-TR and DLD1-TR. The sensitivity of TRAIL-resistant cell lines to TRAIL was periodically examined by PI (Sigma, St. Louis, MO) staining and flow cytometry, and never exceeded 5% cell death as described before.10 (link)
+ Open protocol
+ Expand
6

Apoptosis Induction and Inhibition

Check if the same lab product or an alternative is used in the 5 most similar protocols
For induction of apoptosis the BH3 mimetics A1331852, ABT-199 (Selleck Chemicals, Houston, TX) or S63845 (ApexBio, Houston, TX), and human recombinant TRAIL (R&D Systems, Wiesbaden, Germany) were used. To inhibit cell death zVAD.fmk (Bachem, Heidelberg, Germany) or anti-TRAIL antibody (#2E5, Enzo Life Sciences, Lörrach, Germany) were added to the experiments.
+ Open protocol
+ Expand
7

miR-26b Modulation of Apoptosis

Check if the same lab product or an alternative is used in the 5 most similar protocols
miR-26b mimics and negative control oligonucleotide (NC oligo) were purchased from RiboBio Company (China). The sequences of the above RNA oligos were as follows: miR-26b mimics: 5′-UUCAAGUAAUUCAGGAUAGGU-3′; NC oligo: 5′-UGUAAUAAUGGAACUCGGAUU-3′. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), trypan blue, and Annexin V-FITC Apoptosis Detection Kit were obtained from Sigma-Aldrich (USA). Antibodies for rabbit anti-human Mcl-1 and rabbit anti-human β-actin were purchased from Cell Signaling (USA). Human recombinant TRAIL was obtained from R&D Systems (USA).
+ Open protocol
+ Expand
8

Characterization of Burkitt Lymphoma Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human BL cell lines RAMOS, DG-75, RAJI, BJAB and DAUDI were obtained from the German Collection of Microorganisms and Cell cultures (DSMZ, Braunschweig, Germany) and BL-2, BL-30, Seraphine, BL-60, BL-70 and Salina cells were kindly provided by T. Oellerich, Department of Medicine II, Hematology/Oncology, University Hospital Frankfurt, Germany. All cell lines were authenticated by STR profiling and continuously monitored for mycoplasma contamination. Cells were cultured in RPMI 1640 (Life Technologies), supplemented with 10% or 20% fetal calf serum (FCS) and 1% penicillin/streptomycin (Invitrogen). The bivalent Smac mimetic BV6 was kindly provided by Genentech. The broad-range caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethylketone (zVAD.fmk) was purchased from Bachem, Necrosulfonamide (NSA) from Toronto Research Chemicals Inc., GSK’872 and Necrostatin-1s (Nec-1s) from Merck and Dabrafenib from Selleck Chemicals. Recombinant human TRAIL was obtained from R&D Systems, human recombinant TNFα from PeproTech and human multimeric FASL from AdipoGen. Doxycycline hydrochloride (DOX) was purchased from Sigma-Aldrich. LCL-161 was purchased from Novartis and AT-406, Birinapant and SGI-110 (Guadecitabine) were obtained from Selleck Chemicals. All other chemicals were purchased from Sigma-Aldrich or Carl Roth unless indicated otherwise.
+ Open protocol
+ Expand
9

Evaluation of Novel Apoptosis Inducers

Check if the same lab product or an alternative is used in the 5 most similar protocols
LCL161 was synthesized and provided by Novartis (Basel, Switzerland) under a Material Transfer Agreement (MTA). TG101209 was purchased from Selleckchem (Houston, TX). SD1029 was purchased from EMD Millipore (Billerica, MA). Recombinant human TRAIL and Fas-L were purchased from R&D systems (Minneapolis, MN). Pan-caspase inhibitor Q-VD-OPH, caspase 9 inhibitor Ac-LEHD-CMK and caspase 8 inhibitor Z-IETD-FMK were purchased from EMD Millipore.
+ Open protocol
+ Expand
10

TRAIL-induced Apoptosis in Kidney Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mouse kidney cells (TCMK-1) were a gift from Dr. T.J. Lee (Yeungnam University, Korea). Primary culture of human mesangial cells (Cryo NHMC) were purchased from Clonetics (San Diego, CA, USA), and other cell lines are from the ATCC (Manassas, VA, USA). All cells were maintained in Dulbecco’s modified Eagle’s medium, and supplemented with 10% FBS, 5% antibiotic solution, and 100 μg/mL gentamycin. Garcinol and lactacystin was purchased from Enzo Life Sciences (Ann Arbor, MI, USA). Recombinant human TRAIL and z-VAD-fmk were purchased from R&D (Minneapolis, MN, USA). Calbiochem supplied N-acetyl-l-cysteine (NAC), trolox, and MG132 (San Diego, CA, USA). The following antibodies were used: anti-XIAP, -Bcl-2, -Mcl-1, -survivin, -Cbl, and -Itch (Santa Cruz Biotechnology, Santa Cruz, CA, USA); anti-c-FLIP (ALEXIS Corporation, San Diego, CA, USA); anti-PARP, -DR5, -PSMA5, -PSMD4/S5a, -cleaved caspase-3 (Cell Signaling Technology, Beverly, MA, USA); anti-caspase-3 (Enzo Life Sciences, Ann Arbor, MI, USA); anti-DR4 (Abcam, Cambridge, MA, USA); anti-actin (Sigma-Aldrich, St. Louis, MO, USA). Santa Cruz Biotechnology (Santa Cruz, CA, USA) and Bioneer (Daejeon, Korea) supplied DR5 siRNA and GFP siRNA (control siRNA), respectively. Sigma Chemical Co. supplied other reagents (St. Louis, MO, USA).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!